SCHEDULE: Paradigm BioCapital Discloses Stake in Jade Biosciences

Paradigm BioCapital Advisors LP, along with affiliated entities, has reported beneficial ownership of over 5% of Jade Biosciences, Inc. common stock.

Summary

• Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. have jointly filed a Schedule 13G.
• This filing indicates beneficial ownership of Jade Biosciences, Inc. common stock.
• The total aggregate amount beneficially owned by the reporting persons is 3,106,793 shares, representing 5.1% of the class.
• The Paradigm BioCapital International Fund Ltd. directly beneficially owns 2,738,259 shares, representing 4.5% of the class.
• The filing date, indicating the event requiring this statement, is July 10, 2026.
• The reporting persons certify that the securities were not acquired for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a standard regulatory disclosure of a significant passive ownership stake without providing performance data or strategic insights into Jade Biosciences, Inc.

Positives

• Significant stake disclosed by a notable investment advisor, potentially indicating confidence in Jade Biosciences' future.
• The reporting persons hold sole voting and dispositive power for the shares they beneficially own, suggesting clear control over their investment decisions.
• The filing is a routine disclosure for significant ownership stakes, indicating compliance with regulatory requirements.

Negatives

• The filing does not provide specific financial performance data for Jade Biosciences, Inc., limiting a full assessment of the company's health.
• The disclosure is a Schedule 13G, which is typically filed by passive investors, suggesting no immediate intent to influence company control, which could be seen as a lack of active engagement by the investor.

Risks

• The filing does not explicitly mention any risks associated with Jade Biosciences, Inc. or the investment itself.
• Potential future regulatory changes or market conditions could impact the value of the investment.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Jade Biosciences, Inc. The reporting persons certify that the securities were not acquired for the purpose of influencing control.

Management Comments

• Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by an investment advisor like Paradigm BioCapital is a common disclosure for significant passive stakes in publicly traded companies, particularly within the biotechnology sector where investment firms often take positions in emerging companies.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant passive investor, which may be viewed positively or neutrally depending on market sentiment towards Paradigm BioCapital and Jade Biosciences, Inc.
• Management of Jade Biosciences, Inc.: Awareness of a significant passive shareholder is a standard aspect of public company governance.
• Potential Investors: The filing provides information about ownership structure, which is a factor in investment analysis.

Next Steps

• Continued monitoring of Jade Biosciences, Inc. for future disclosures or operational updates.
• Potential for Paradigm BioCapital to increase or decrease its stake in Jade Biosciences, Inc., which would trigger further filings.

Key Dates

Keywords

Jade Biosciences, Paradigm BioCapital, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Management, Biotechnology